Inflammatory intestinal diseases cover mainly ulcer and cronosis, with complex mechanisms and traditional treatments that are less effective for some patients. The emergence of biological agents has brought new light and significant advantages to the treatment of inflammatory enteropathy.
i. Precision target-directional inflammation factors, efficient induction and mitigation. Biological agents can be specific to the key inflammation factors involved in the inflammation of intestinal disease, such as cancer cause of death – α (TNF-α), white cell media, etc. In the case of TNF-α, for example, it can be accurately combined with TNF-α, disrupting its biological activity and thus rapidly inhibiting overactive inflammation in the intestinal tract. This allows for a rapid and significant reduction of clinical symptoms such as diarrhoea, abdominal pain and mucous sepsis, which significantly reduces the duration of disease activity, improves the quality of life of patients and enables them to return to normal life and work more quickly.
2. Strongly promotes mucous membrane healing and improves intestinal function. In the case of inflammatory intestinal diseases, intestinal mucous membrane is chronically immersed in inflammation, with ulcer and ulcer damage, which seriously affects normal intestinal absorption, excretion and barrier functions. By inhibiting inflammatory reactions, biological agents create a favourable micro-environment for the restoration of intestinal mucous membranes, which can effectively contribute to the regeneration and repair of mucous epipelagic cells and accelerate the healing of ulcer surfaces. The mucous healing not only helps to improve the digestive and absorption function of the intestinal tract and to reduce the loss of nutrients, but also reduces the risk of serious complications such as intestinal perforation, narrowness and fistula formation, with a positive impact on the long-term prognosis of the disease.
Effectively reduce the risk of recurrence and maintain the chronic re-emergence of inflammatory enteropathy, which can lead to an increase in intestinal damage and increase the difficulty of treatment and medical costs. When used for long-term maintenance, biological agents sustainably control potential inflammation activities in the intestinal tract and stabilize the intestinal environment, thus significantly reducing the recurrence of disease. This means that the patient is able to maintain a state of disease relief over a longer period of time, reducing the number of hospitalizations, surgical interventions and dependence on other drugs resulting from the recurrence of the disease, and providing a more stable and sustainable health security for the patient.
Biological agents have a certain advantage in safety compared to traditional immunosuppressants such as sugar cortex hormones. The long-term use of traditional medicines is often accompanied by more systemic adverse effects, such as the potential for osteoporosis, high blood pressure, diabetes and increased risk of infection. Biological agents, by virtue of their high target orientation, are primarily responsible for local inflammation targets in the intestinal tract, with relatively few systemic adverse reactions and better patient tolerance, making them more conducive to the overall health of patients during long-term treatment and reducing the additional health risks and treatment burdens associated with adverse drug reactions.
In summary, biological agents have demonstrated unique advantages in the treatment of inflammatory enteropathy, which has brought better treatment to patients, lower risk of relapse and relatively safer treatment experiences, and have become important tools in the field of inflammatory enteropathy treatment, significantly improving the quality of survival and premeditation of patients with inflammatory enteropathy.
